Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Scotia submits additional data to FDA for Foscan NDA

Nov. 30, 2000

U.K. scientists investigate novel series of antitumor agents

Nov. 30, 2000

Maxim receives SBIR grant for development of caspase-inducing drugs

Nov. 30, 2000

FeRx and Elan to develop MTC-DOX for treatment of liver cancer

Nov. 30, 2000

Deltagen obtains license to develop potential AML treatment

Nov. 30, 2000

Enhanced expression of p21 associated with responses to rAd-p53 gene therapy in NSCLC

Nov. 29, 2000

PK-11195 is able to sensitize cholangiocarcinoma cells to radiation-induced apoptosis

Nov. 29, 2000

Favorable pharmacokinetic and tolerability profile for Angiozyme in humans

Nov. 29, 2000

Antitumor agents from Spanish university induce apoptosis

Nov. 28, 2000

Oncologic Drugs Advisory Committee meeting in mid-December has a full agenda

Nov. 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...